News Releases

News & Events

News Releases

Synteract Presenting and Exhibiting at DIA 2014 50th Annual Meeting

San Diego-based clinical research organization delivers answers to help take time and cost out of drug development

SAN DIEGO – June 4, 2014 – Synteract, a full-service, international contract research organization (CRO), is presenting and exhibiting at the Drug Information Association (DIA) 2014 50th Annual Meeting June 16-19 at the San Diego Convention Center. The company will exhibit at booth #1731 where a team of its own international experts will speak on trending topics important to the biopharma industry and provide answers to issues impacting the efficiencies and speed of clinical trials.

With numerous questions surrounding the increasingly complex drug development process, Synteract’s theme for DIA 2014 is: “We have your answers.” Synteract experts are prepared to discuss sponsor project needs and how the company can support all aspects of international, phase I-IV programs. Synteract will also have its own recruitment professionals present to discuss career openings at the company, particularly in the area of medical, regulatory and drug safety, project management, clinical operations and quality assurance.

“As we approach this important industry event, our sights remain clearly focused on client collaboration, communication and service excellence,” says Synteract CEO Wendel Barr. “We have been a trusted clinical trial outsourcing partner to clients for many years because of our ability to provide clear advice, clear data, clear results, and overall, clear answers. We are pleased that key members of our global clinical development team will share their expertise and guidance in person during DIA in San Diego, the city where we are headquartered.”

Specific speaker presentations include:

  • “Challenges & Opportunities in Drug Development” presented by Wendel Barr, CEO, on Monday, June 16 at 1 p.m. and Tuesday, June 17 at 1 p.m.

  •  “EDC Platforms: What’s Right for You?” presented by Toby Odenheim, Director, Vendor Management, on Monday, June 16 at 11:30 a.m., Tuesday, June 17 at 2:30 p.m. and Wednesday, June 18 at 10 a.m.
  • “New EU CT Regulation: the Good, the Bad, the Ugly” presented by Dr. Martine Dehlinger-Kremer, VP, Global Medical and Regulatory Affairs, on Monday, June 16 at 2:30 p.m., Tuesday, June 17 at 11:30 a.m. and Wednesday, June 18 at 11:30 a.m.

  • “Risk-based Monitoring: What It Needs To Be” presented by Philip Doren, Ph.D., VP, Global Biometrics, on Monday, June 16 at 4 p.m., Tuesday, June 17 at 10 a.m. and Wednesday, June 18 at 2 p.m.

To make an appointment in advance, please contact Matt Smith, SVP Business Development, at 760-268-8200 or The company will also post live updates from DIA on Twitter @Synteract and by using #DIA2014answers. Visit for more information and to sign up to receive Synteract experts’ presentations after DIA 2014.

About Synteract 

Synteract is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. Synteract has conducted Phase I-IV studies on six continents and in more than 50 countries, offering expertise across multiple therapeutic areas and with notable depth in oncology, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision” philosophy and ICD+ approach, Synteract provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data so clients get to decision points faster.

Beth Walsh


Contact Synteract

Tell us how to stay in touch with you: